메뉴 건너뛰기
JNCCN Journal of the National Comprehensive Cancer Network
Volumn 9, Issue SUPPL. 3, 2011, Pages
A quick REMS update and a clinical focus
Author keywords

[No Author keywords available]
Indexed keywords

CANCER RISK; DRUG INFORMATION; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HEALTH CARE POLICY; MEDICAL LITERATURE; MEDICAL SOCIETY; PRACTICE GUIDELINE; PUBLICATION;
EID: 79952734115     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2011.0129     Document Type: Editorial
Times cited : (1)
References (3)
  • 1
    • 79952712468 scopus 로고    scopus 로고
    • Web site. Available at: Accessed November 8, 2010
    • Stakeholder Meeting on PDUFA V Reauthorization. U.S. Food and Drug Administration Web site. Available at: http://www.fda.gov/downloads/ForIndustry/ UserFees/PrescriptionDrugUserFee/UCM229610.pdf. Accessed November 8, 2010.
    • Stakeholder Meeting on PDUFA V Reauthorization
  • 2
    • 77953691179 scopus 로고    scopus 로고
    • Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia
    • Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251-2259.
    • (2010) N Engl J Med , vol.362 , pp. 2251-2259
    • Saglio, G.1    Kim, D.W.2    Issaragrisil, S.3
  • 3
    • 77953725855 scopus 로고    scopus 로고
    • Dasatinib versus imatinib in newly diagnosed chronicphase chronic myeloid leukemia
    • Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronicphase chronic myeloid leukemia. N Engl J Med 2010;362:2260-2270.
    • (2010) N Engl J Med , vol.362 , pp. 2260-2270
    • Kantarjian, H.1    Shah, N.P.2    Hochhaus, A.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.